Anti Cancer Medication

Approx. Rs 35,750 / BoxGet Latest Price

Vectibix (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese hamster ovary) cells.

Vectibix is a sterile, colorless, pH 5.6 to 6.0 liquid for intravenous (IV) infusion, which may contain a small amount of visible translucent-to-white, amorphous, proteinaceous, panitumumab particulates. Each single-use 5 mL vial contains 100 mg of panitumumab, 29 mg sodium chloride, 34 mg sodium acetate, and Water for Injection, USP. Each single-use 10 mL vial contains 200 mg of panitumumab, 58 mg sodium chloride, 68 mg sodium acetate, and Water for Injection, USP. Each single-use 20 mL vial contains 400 mg of panitumumab, 117 mg sodium chloride, 136 mg sodium acetate, and Water for Injection, USP.

Vectibix is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use:

• As first-line therapy in combination with FOLFOX [see Clinical Studies].
• As monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy

The recommended dose of Vectibix is 6 mg/kg, administered as an intravenous infusion over 60 minutes, every 14 days. If the first infusion is tolerated, administer subsequent infusions over 30 to 60 minutes. Administer doses higher than 1000 mg over 90 minutes [see Preparation and Administration].

Appropriate medical resources for the treatment of severe infusion reactions should be available during Vectibix infusion

100 mg panitumumab in 5 mL (20 mg/mL) single-use vial.

200 mg panitumumab in 10 mL (20 mg/mL) single-use vial.

400 mg panitumumab in 20 mL (20 mg/mL) single-use vial.

Approx. Rs 400 / VialGet Latest Price

Additional Information:

Approx. Rs 250 / UnitGet Latest Price

Additional Information:

Approx. Rs 18,060 / UnitGet Latest Price

Additional Information:

Approx. Rs 4,995 / UnitGet Latest Price

Approx. Rs 10,400 / BottleGet Latest Price

Approx. Rs 21,500 / BottleGet Latest Price

Approx. Rs 660 / PER TEN TABGet Latest Price

Veenat is used in treating chronic myelogenous leukemia (cml), gastrointestinal stromal tumors (gists),leukemias and other cancers. Cancers are characterized by uncontrolled growth of cells, and leukemia is a specific type of cancer characterized by uncontrolled proliferation of white blood cells.

below are the competitors brands available with d. Vijay pharma pvt. Ltd. Kindly see the table file below.

Additional Information:

Approx. Rs 4,699 / BottleGet Latest Price

Additional Information:

Approx. Rs 7,975 / VialGet Latest Price

Additional Information:

Product Price :Get Latest Price

• Sterile single dose vial
• For I.V. infusion after dilution

Additional Information:

Product Price :Get Latest Price

Additional Information:

Approx. Rs 48,800 / StripGet Latest Price

Additional Information:

Approx. Rs 7,955 / TWENTY EIGHT TABGet Latest Price

Regorafenib is used to treat cancer of the colon and rectum. It is also used to treat liver cancer and a certain cancer of the digestive system (gastrointestinal stromal tumor). It works by slowing or stopping the growth of cancer cells.

Common side effects :

weakness/fatigue,
loss of appetite and decreased food intake,
hand-foot skin reaction (HFSR),
diarrhea,
stomach pain,
weight loss,
infection,
high blood pressure (hypertension),

Additional Information:

Approx. Rs 13,500 / TabletGet Latest Price

Votrient 200 mg film-coated tablets

Each film-coated tablet contains 200 mg pazopanib (as hydrochloride).

Votrient 400 mg film-coated tablets

Each film-coated tablet contains 400 mg pazopanib (as hydrochloride).

Renal cell carcinoma (RCC)

Votrient is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.

Soft-tissue sarcoma (STS)

Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Efficacy and safety has only been established in certain STS histological tumour subtypes .

Votrient treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal product

Pazopanib should not be used in children younger than 2 years of age because of safety concerns with regard to organ growth and maturation.

The safety and efficacy of pazopanib in children aged 2 to 18 years of age have not yet been established. No data are available.

Additional Information:

Product Price :Get Latest Price

• Pharmacy Medicine 
• Keep out of reach of children

Additional Information:

Product Price :Get Latest Price

Available with us are highly effective medicines including Thalix, which is widely demanded in the market. These medicines ensure effective results, accurate formulation and safe usage. We supply these medicines to our clients spread all across the nation. These are sourced from reliable vendors of the industry, who hold vast experience in the domain. Thalix is available in the form of 50 mg capsule, 100 mg capsule and 200 mg capsule.

Additional Information: